文献速递泌尿生殖MR

MRI衍生特征对前列腺癌根治性放疗后生化复发的预后价值

Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancer.
PubMed 文献 · Abdom Radiol (NY) · 2025-09-20

回顾性单机构研究纳入54例接受根治性放疗的局限性前列腺癌患者,评估治疗前多参数MRI特征对Phoenix标准定义生化复发的预测价值。中位随访74.4个月,10例(18.5%)出现生化复发;多因素分析中神经血管束侵犯是唯一独立预测因子(OR 3.16,95%CI 1.59-6.28,p=0.001),特异度86.4%、阴性预测值92.7%。

要点

  • 治疗前MRI示神经血管束侵犯是放疗后生化复发的独立预测因子(OR 3.16)。
  • 神经血管束侵犯预测复发的特异度86.4%,阴性预测值92.7%。
  • 精囊侵犯、前列腺外侵犯、肿瘤总体积在单因素分析中与复发强相关。

核心结论

  • 治疗前MRI显示的神经血管束侵犯可独立预测局限性前列腺癌根治性放疗后的生化复发,提示应将影像学标准纳入风险分层。

研究设计与样本

  • 回顾性单机构研究,纳入2015年1月至2019年12月接受初始放疗的前列腺癌患者54例(平均年龄76.57±7.77岁),治疗前均行多参数MRI(有或无直肠内线圈),主要终点为Phoenix标准定义的生化复发。

关键影像表现/征象

  • 治疗前多参数MRI评估定性及定量影像特征,重点包括肿瘤总体积、前列腺外侵犯、神经血管束侵犯和精囊侵犯。
  • 单因素分析中肿瘤总体积OR 4.28(95%CI 1.59-11.57)、前列腺外侵犯OR 8.57(95%CI 1.61-45.73)、神经血管束侵犯OR 14.78(95%CI 2.97-73.44)、精囊侵犯OR 15.00(95%CI 2.94-76.56)与生化复发强相关。

诊断标准与关键数值

  • 生化复发采用Phoenix标准定义。
  • 多因素分析中神经血管束侵犯为唯一独立预测因子:OR 3.16(95%CI 1.59-6.28,p=0.001),特异度86.4%,阴性预测值92.7%。
  • 单因素分析中临床T分期OR 2.24(95%CI 1.11-4.56)、ISUP分级OR 1.86(95%CI 1.03-3.37)、NCCN风险分组OR 2.55(95%CI 1.16-5.62)为显著预测因子。

临床应用与阅片要点

  • 阅片报告应明确描述神经血管束侵犯、精囊侵犯、前列腺外侵犯及肿瘤总体积,因这些MRI特征与放疗后生化复发相关。
  • 神经血管束侵犯阴性时阴性预测值达92.7%,可辅助识别放疗后复发风险较低的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: To evaluate whether pretreatment multiparametric MRI features can predict biochemical recurrence in patients with localized prostate cancer treated with radiation therapy of curative intent.

METHODS: This retrospective single-institution study analyzed patients with prostate cancer who underwent primary radiotherapy between January 2015 and December 2019. All patients underwent pretreatment multiparametric MRI, with or without endorectal coil. Clinical, pathological and MRI features were assessed, with emphasis on qualitative and quantitative imaging characteristics. Univariate binary logistic regression identified significant predictors of recurrence. Variables showing significance (p < 0.05) were included in forward stepwise logistic regression analysis. The primary endpoint was biochemical recurrence, defined by Phoenix criteria.

RESULTS: The study included 54 patients (mean age 76.57 ± 7.77 years), with 10 patients (18.5%) experiencing biochemical recurrence at a median follow-up of 74.4 months. In univariate analysis, clinical T-stage (OR: 2.24, 95% CI: 1.11-4.56), ISUP grade (OR: 1.86, 95% CI: 1.03-3.37) and NCCN risk groups (OR: 2.55, 95% CI: 1.16-5.62) were significant predictors. Among MRI parameters, total tumor volume (OR: 4.28, 95% CI: 1.59-11.57), extraprostatic extension (OR: 8.57, 95% CI: 1.61-45.73), neurovascular bundle invasion (NBI) (OR: 14.78, 95% CI: 2.97-73.44), and seminal vesicle invasion (OR: 15.00, 95% CI: 2.94-76.56) showed strong associations with recurrence. In stepwise multivariate analysis, NBI emerged as the sole independent predictor (OR: 3.16, 95% CI: 1.59-6.28, p = 0.001), with 86.4% specificity and 92.7% negative predictive value.

CONCLUSION: NBI on pretreatment MRI independently predicts biochemical recurrence in patients with localized prostate cancer treated with radiation therapy, highlighting the need to refine risk stratification by incorporating imaging criteria.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Herold A, Pohl M, Korn SM, et al. Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancer. Abdom Radiol (NY). 2025. PMID: 40974477. doi:10.1007/s00261-025-05199-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。